Business Context and Reporting Period
This Form 8-K is a current report filed by Artelo Biosciences, Inc. on March 17, 2026. The filing primarily addresses the completion of a corporate action and the subsequent republishing of financial statements to reflect this change.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures within the text of the report. Instead, it references Exhibit 99.1, which contains the audited financial statements for the fiscal years ended December 31, 2024, and 2025, republished to account for a change in total par value.
Material Changes
The primary material event reported is a one-for-three (1-for-3) reverse stock split effective as of March 10, 2026. Key impacts include:
- Outstanding Shares: Reduced from 2,124,772 to approximately 708,323.
- Authorized Common Stock: Reduced from 500,000,000 to 166,666,667.
- Authorized Preferred Stock: Reduced from 69,444 to 23,148.
- Par Value: Remained unchanged at $0.001 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is strictly procedural, focusing on the mechanics of the reverse split and the incorporation of updated financial exhibits.
Investor Verification Checklist
- Verify the updated share count and trading symbol (ARTL) on The NASDAQ Stock Market, LLC.
- Review Exhibit 99.1 for the republished audited financial statements for fiscal years 2024 and 2025 to assess the company's actual financial position.
- Confirm the impact of the reverse split on existing holdings and the reduction in authorized share capital.